RELA
protein-codingRELA proto-oncogene, NF-kB subunit, the group of IPT domain containing|NF-kappa B complex subunits
Gene summary
NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]
- NFKB3
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~9.5 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0035694
Submitter: ClinGen
*RELA* was first reported in relation to autosomal dominant combined immunodeficiency due to *RELA* haploinsufficiency in 2017 (Badran YR, et al., 2017, PMID: 28600438). *RELA* encodes RelA/p65 which is a key component of the canonical pathway of NFκB, and associates with p50/NFκB1for nuclear translocation and cytokine gene transcription. Signaling through the NF-κB pathway is important for maintaining self-tolerance and regulation of the immune response. *RELA* haploinsufficiency results in impaired NF-κB activation downstream of TLR and TNF stimulation, followed by impaired up-regulation of antiapoptotic genes and increased stromal cell apoptosis. This disorder is characterized predominantly by chronic mucocutaneous ulceration; however, the clinical phenotype broadens to include Behçet’s syndrome and irritable bowel disease. Genetic evidence was included in this curation from four probands in four publications (PMIDs: 28600438, 32969189, 29305315, 35412596). The four reported variants include splice site, frameshift, and nonsense. Experimentally, this gene-disease relationship is supported by its function in the activation of NF-κB-dependent transcription and to prevent apoptosis (PMID: 12881425), which is altered in in HEK293T cells transfected with mutant *RELA* (PMID: 32969189) and in patients, resulting in increased TNF-induced stromal cell death (PMID: 28600438). Defective activation of NF-κB-dependent transcription was rescued in patient cells with expression of WT *RELA* (PMID: 28600438). Furthermore, a Rela+/− mouse model recapitulated the defective NF-κB-dependent transcription and cutaneous ulceration observed in patients (PMID: 28600438). In summary, there is Definitive evidence to support this gene-disease relationship. This has been repeatedly demonstrated in both research and the clinical diagnostic setting and has been upheld over time.
Inheritance Pattern: AD
Disease ID:MONDO:0032659
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0032659
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0032659
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Allergy/Immunology/Infectious
Intervention: Allergy/Immunology/Infectious
Rationale: Individuals can have chronic mucocutaneous ulcerations, and medical management (with a tumor necrosis factor inhibitor) has been described as beneficial
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to RELA variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_021975.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 3 | 137 | 4 | 144 | ||
| missense | 1 | 212 | 9 | 222 | ||
| nonsense | 12 | 8 | 1 | 21 | ||
| start loss | 1 | 1 | ||||
| frameshift | 17 | 5 | 4 | 26 | ||
| splice donor/acceptor (+/-2bp) | 1 | 3 | 3 | 7 | ||
| Total | 30 | 17 | 224 | 146 | 4 | 421 |
Highest pathogenic variant AF is 0.000006569439
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_068810.3 | 11 | MANE Select | |
| Ensembl | ENSP00000384273.3 | 11 | MANE Select | |
| RefSeq | NP_001138610.1 | 11 | Standard | |
| RefSeq | NP_001230913.1 | 11 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| rela | Danio rerio | Structure: whole organism Quality: viability abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- PI3K-Akt signaling pathway - Homo sapiens (human)
- Chronic myeloid leukemia - Homo sapiens (human)
- Relaxin signaling pathway - Homo sapiens (human)
- Adipocytokine signaling pathway - Homo sapiens (human)
- T cell receptor signaling pathway - Homo sapiens (human)
Biological Process
- negative regulation of transcription by RNA polymerase II
- liver development
- hair follicle development
- stimulatory C-type lectin receptor signaling pathway
- acetaldehyde metabolic process
Molecular Function
- RNA polymerase II regulatory region sequence-specific DNA binding
- RNA polymerase II proximal promoter sequence-specific DNA binding
- RNA polymerase II distal enhancer sequence-specific DNA binding
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA-binding transcription repressor activity, RNA polymerase II-specific
Cellular Component
- nuclear chromatin
- nucleus
- nucleoplasm
- transcription factor complex
- nucleolus
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000406246
- Coding exons
- 11
- Length
- 9499
- Individuals with no LoFs
- 125293
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 5
- Defined
- 125298
- p
- 0.0000200
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.45 | 208 | 334 | 0.623 | 0.0000208 | 3514 |
| Missense (PolyPhen) | 41 | 127.77 | 0.3209 | 1334 | ||
| Synonymous | -0.833 | 145 | 133 | 1.09 | 0.00000774 | 1176 |
| Loss of Function | 4.56 | 1 | 26.2 | 0.0382 | 0.00000163 | 261 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0.000032 | 0.000029 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0.000049 | 0.000046 | rare |
| European (Non-Finnish) | 0.000028 | 0.000026 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA- NFKB1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF-kappa-B heterodimeric RELA-NFKB1 and RELA-REL complexes, for instance, function as transcriptional activators. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I-kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Beside its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681). The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin- mediated activation of IL-8 expression. {ECO:0000269|PubMed:10928981, ECO:0000269|PubMed:12748188, ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17000776, ECO:0000269|PubMed:17620405, ECO:0000269|PubMed:19058135, ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:20547752}.;
- Disease
- DISEASE: Note=A chromosomal aberration involving C11orf95 is found in more than two-thirds of supratentorial ependymomas. Translocation with C11orf95 produces a C11orf95-RELA fusion protein. C11orf95-RELA translocations are potent oncogenes that probably transform neural stem cells by driving an aberrant NF- kappa-B transcription program (PubMed:24553141). {ECO:0000269|PubMed:24553141}.;
Recessive Scores
- pRec
- 0.754
Intolerance Scores
- LoFtool
- 0.248
- RVIS EVS
- -0.69
- RVIS percentile EVS
- 15.12
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 1.00
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |